Dr. Ezra Cohen is an internationally-renowned translational researcher. He has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted therapy. His recent National Institutes of Health-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance. He was recently appointed as chair of the NCI head and neck cancer steering committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease. Dr. Cohen chairs the protocol review and monitoring committee (PRMC) and serves as a member of the Cancer Council, C3 steering committee and the cancer center’s executive committee.